Last updated 4 days ago
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
300 patients around the world
Available in Chile
Merck Sharp & Dohme LLC
5Research sites
300Patients around the world
This study is for people with
Myeloproliferative syndromes
Essential thrombocythemia
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Centro de Investigación Clínica Bradford Hill - Santiago, Región Metropolitana
Recruiting
Biocenter
Recruiting
IC La Serena Research - La Serena
Recruiting
Inmunocel
Recruiting
Clínica Alemana
Recruiting
SponsorMerck Sharp & Dohme LLC
Conditions
Essential thrombocythemia
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06456346
